

NeutriSci International Inc.

Condensed Consolidated Interim Financial Statements
(Unaudited – Prepared by Management)
(Expressed in US Dollars)

As at and for the nine months ended September 30, 2015

NeutriSci International Inc.
(the “Company”)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
As at and for the nine months ended September 30, 2015

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Management of the Company is responsible for the preparation of the accompanying unaudited condensed consolidated interim financial statements. The unaudited condensed consolidated interim financial statements have been prepared using accounting policies in compliance with International Financial Reporting Standards for the preparation of interim financial statements and are in accordance with IAS 34 – Interim Financial Reporting.

The Company’s auditor has not performed a review of these condensed consolidated interim financial statements in accordance with the standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity’s auditor.

NeutriSci International Inc.

Consolidated Statements of Financial Position

(Expressed in US dollars)

As at

	September 30, 2015	December 31, 2014
Assets		
Current Assets		
Cash	\$ 161,293	\$ 848,770
Trade receivables	5,184	-
Due from related parties (Note 8)	48,137	18,736
Goods and services tax receivable	51,345	60,752
Inventory (Note 5)	1,217,780	1,167,369
Prepaid expenses	11,842	85,308
Total current assets	1,495,581	2,180,935
Equipment (Note 6)	19,465	25,461
Intangible asset	9,027	-
Total Assets	\$ 1,524,073	\$ 2,206,396
Liabilities and Shareholders' Equity		
Current Liabilities		
Accounts payable and accrued liabilities	\$ 344,679	\$ 311,121
Notes payable (Note 7)	574,659	1,094,730
	919,338	1,405,851
Shareholders' Equity		
Share capital (Note 9)	18,527,673	17,724,066
Warrants (Note 9)	41,402	41,402
Contributed surplus	1,618,566	1,393,651
Deficit	(19,594,865)	(18,338,868)
Accumulated other comprehensive loss	11,959	(19,706)
	604,735	800,545
Total Liabilities and Shareholders' Equity	\$ 1,524,073	\$ 2,206,396
Nature and continuance of operations (Note 1)		
Related party transactions (Note 8)		
Subsequent events (Note 11)		

Approved on Behalf of the Board on November 27, 2015:

"Scott Ackerman"

Scott Ackerman – CEO

"Robert Chisholm"

Robert Chisholm – CFO

The accompanying notes are an integral part of these condensed consolidated interim financial statements

NeutriSci International Inc.**Condensed Consolidated Interim Statements of Loss and Comprehensive Loss**

(Unaudited – Prepared by Management)

(Expressed in US dollars)

	For the three months ended September 30, 2015		For the nine months ended September 30, 2015		For the twelve months ended September 30, 2014
		2014			
Sales Revenue	\$ 2,043	\$ 25,642	\$ 21,920	\$ 64,971	
Cost of Sales	980	(701)	10,179	13,457	
	1,063	26,343	11,741	51,514	
Expenses					
Operating expenses (Note 10)	281,346	144,491	979,459	837,355	
General and administrative costs (Note 10)	52,791	35,952	270,948	210,193	
Finance costs (Note 10)	11,578	130,515	17,331	811,124	
Gain on forgiveness of debt	-	-	-	(57,334)	
	345,715	310,958	1,267,738	1,801,338	
Loss for the period	(344,652)	(284,615)	(1,255,997)	(1,749,824)	
Translation gain	74,170	-	31,665	-	
Loss and comprehensive loss for the period	\$ (270,482)	\$ (284,615)	\$ (1,224,332)	\$ (1,749,824)	
Weighted average number of shares outstanding – basic and diluted	34,845,093	13,350,024	25,394,147	12,540,754	
Basic and diluted loss per share	\$ (0.01)	\$ (0.02)	\$ (0.05)	\$ (0.14)	

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

NeutriSci International Inc.

Condensed Consolidated Interim Statements of Shareholders' Equity
(Unaudited – Prepared by Management)
(Expressed in US dollars)

	Number of Common Shares				Number of Preferred Shares		Other Comprehensive					
	Series A	Series B	Common	Series 1	Series A, B, and C	Share Capital Amount	Subscription Receipts	Contributed Surplus	Warrants	Items	Deficit	Total
September 30, 2013	8,682,780	2,227,500	-	669,708	-	\$ 10,042,078	\$450,651	\$ 2,065,575	\$238,891	\$ -	\$(8,902,747)	\$3,894,448
Class A – Issuance of shares	472,500	-	-	-	-	457,822	(450,651)	-	-	-	-	7,171
Class A – Shares for finance fee	20,000	-	-	-	-	19,600	-	-	-	-	-	19,600
Series 1 Preferred Shares – anti-dilution clause	-	-	-	950	-	3,724	-	-	-	-	-	3,724
Class A – Shares for service	34,000	-	-	-	-	34,494	-	-	-	-	-	34,494
Class A – Shares for service	98,668	-	-	-	-	98,668	-	-	-	-	-	98,668
Class A – Options granted	-	-	-	-	-	-	-	40,571	-	-	-	40,571
Class A – Options exercised	1,450,000	-	-	-	-	1,462,714	-	(1,344,821)	-	-	-	117,893
Class A – Warrants issued	-	-	-	-	-	(502)	-	-	502	-	-	-
Class A – Shares to settle debt	235,294	-	-	-	-	215,976	-	-	-	-	-	215,976
Net loss	-	-	-	-	-	-	-	-	-	-	(1,749,824)	(1,749,824)
September 30, 2014	10,993,242	2,227,500	-	670,658	-	\$ 12,334,574	\$ -	\$ 761,325	\$239,393	\$ -	\$(10,652,571)	\$2,682,721
December 31, 2014	-	-	14,283,766	-	22,980,380	\$ 17,724,066	\$ -	\$ 1,393,651	\$ 41,402	\$ (19,706)	\$(18,338,868)	\$ 800,545
Conversion of Preferred Series A shares	-	-	6,758,938	-	(6,758,938)	-	-	-	-	-	-	-
Conversion of Preferred Series B shares	-	-	8,110,723	-	(8,110,723)	-	-	-	-	-	-	-
Conversion of Preferred Series C shares	-	-	8,110,719	-	(8,110,719)	-	-	-	-	-	-	-
Shares issued for services	-	-	200,000	-	-	120,000	-	-	-	-	-	120,000
Share issuance (less finder's fee)	-	-	2,222,216	-	-	295,600	-	-	-	-	-	295,600
Share issuance (less finder's fee)	-	-	1,200,000	-	-	159,682	-	-	-	-	-	159,682
Share issuance	-	-	1,722,333	-	-	228,325	-	-	-	-	-	228,325
Share-based compensation	-	-	-	-	-	-	-	224,915	-	-	-	224,915
Translation loss	-	-	-	-	-	-	-	-	-	31,665	-	31,665
Net loss	-	-	-	-	-	-	-	-	-	-	(1,255,997)	(1,255,997)
September 30, 2015	-	-	42,608,695	-	-	\$ 18,527,673	\$ -	\$ 1,618,566	\$ 41,402	\$ 11,959	\$(19,594,865)	\$ 604,735

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

NeutriSci International Inc.

Condensed Consolidated Interim Statements of Cash Flows
(Unaudited – Prepared by Management)
(Expressed in US dollars)

	For the nine months ended September 30, 2015	For the twelve months ended September 30, 2014
Operating Activities:		
Net loss	\$ (1,255,997)	\$ (1,749,824)
Non-cash items included in net loss		
Accretion of note payable	-	281,546
Accrued interest	6,018	-
Amortization	5,996	10,082
Gain on settlement of debt	-	(57,334)
Share-based compensation	224,915	41,073
Share-based payments	120,000	215,977
Net change in operating assets and liabilities		
Trade receivables	(5,184)	(190,833)
Goods and services tax receivable	9,407	(19,507)
Accounts payable and accrued liabilities	33,558	502,970
Due from/to related parties	(29,401)	75,315
Inventory	(50,411)	79,355
Prepaid expenses	73,466	12,624
	(867,633)	(798,556)
Investing Activities:		
Intangibles	(9,027)	-
Purchase of property and equipment	-	(6,454)
	(9,027)	(6,454)
Financing Activities:		
Repayment of Notes payable	(550,000)	-
Increase in loan payable	74,687	203,613
Proceeds from share issuance	632,831	7,171
	157,518	210,784
Impact of foreign exchange on cash	31,665	-
Decrease in cash for the period	(687,477)	(594,226)
Cash, beginning of the period	848,770	594,377
Cash, ending of the period	\$ 161,293	\$ 151
Supplementary Information:		
Cash paid during the period for interest expense	\$ -	\$ -
Cash paid during the period for income taxes	\$ -	\$ -

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

NeutriSci International Inc.

Notes to the Condensed Consolidated Interim Financial Statements
(Unaudited – Prepared by Management)
(Expressed in US dollars)
As at and for the nine months ended September 30, 2015

1. NATURE OF OPERATIONS AND GOING CONCERN

NeutriSci International Inc. (the "Company" or "NeutriSci") was incorporated under the laws of the Province of Alberta on September 9, 2009 and was continued into British Columbia under the BCBCA on November 26, 2014 in conjunction with the reverse take-over of Disani Capital Corp. ("Disani"). The Company's shares are listed on Tier 2 of the TSX Venture Exchange (the "Exchange") under the symbol "NU". The Company's head office is at 4015 - 1st Street SE, Calgary, Alberta T2G 4X7 and the Company's registered office is 2200-885 West Georgia Street, Vancouver BC, Canada, V6C 3E8.

NeutriSci is focused on the market development for its nutraceutical products.

The Company has a history of losses and anticipates further losses in the development of its business. As at September 30, 2015, the Company has an accumulated deficit of \$19,594,865 (December 31, 2014 - \$18,338,868). Continuing business as a going concern is dependent upon the success of the NeuEnergy™ and BluScience™ products in the retail storefront and online markets, the existing cash flows, and the ability of the Company to obtain additional debt or equity financing all of which are uncertain. These material uncertainties may cast significant doubt on the Company's ability to continue as a going concern.

These condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") under the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than a process of forced liquidation. These condensed consolidated interim financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

2. BASIS OF PRESENTATION

These condensed consolidated interim financial statements have been prepared using accounting policies consistent with IFRS as issued by the International Accounting Standard Board ("IASB") and in accordance with International Accounting Standards ("IAS") 34, Interim Financial Reporting, using accounting policies that the Company expects to adopt in its annual consolidated financial statements for the year ended December 31, 2015. These condensed consolidated interim financial statements do not include all of the information required for the annual consolidated financial statements and should be read in conjunction with the Company's most recent audited consolidated financial statements for the year ended December 31, 2014, which are available on www.sedar.com.

The condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries:

Name of Subsidiary	Ownership	Activity
Britlor Health and Wellness Inc.	a Nevada State corporation	Inactive company
1580306 AB Ltd.	a company incorporated in the province of Alberta	Inactive company
NeutriSci International Corp.	a company incorporated in the province of Alberta	Engaged in the production and sale of nutraceutical products.

These condensed consolidated interim financial statements are presented in US dollars, which is the functional currency of the Company, and were authorized for issuance by the Board of Directors on November 27, 2015.

NeutriSci International Inc.

Notes to the Condensed Consolidated Interim Financial Statements
(Unaudited – Prepared by Management)
(Expressed in US dollars)
As at and for the nine months ended September 30, 2015

3. SIGNIFICANT ACCOUNTING POLICIES

These condensed consolidated interim financial statements have been prepared on the historical cost basis, except for financial instruments classified as financial instruments at fair value through profit or loss, which are stated at their fair value. In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except for the statement of cash flows.

The accounting policies applied in these condensed consolidated interim financial statements are the same as those applied in the Company's audited consolidated financial statements for the year ended December 31, 2014, which are available on www.sedar.com and reflect all of the adjustments necessary for fair presentation in accordance with IAS 34. There is no material impact on these condensed consolidated interim financial statements resulting from changes in accounting standards during the period.

Accounting standards or amendments to existing accounting standards that have been issued but have future effective dates are either not applicable or are not expected to have a significant impact on the Company's financial statements.

4. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The preparation of the condensed consolidated interim financial statements in conformity with International Financial Reporting Standards ("IFRS") requires management to make estimates, judgements and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

(a) Critical accounting estimates

Critical accounting estimates are estimates and assumptions made by management that may result in a material adjustment to the carrying amount of assets and liabilities within the next financial year:

- **Income taxes** - Tax provisions are based on enacted or substantively enacted laws. Changes in those laws could affect amounts recognized in profit or loss both in the period of change, which would include any impact on cumulative provisions, and future periods. Deferred tax assets, if any, are recognized to the extent it is considered probable that those assets will be recoverable. This involves an assessment of when those deferred tax assets are likely to reverse.
- **Fair value of stock options and warrants** - Determining the fair value of warrants and stock options requires judgments related to the choice of a pricing model, the estimation of stock price volatility, the expected forfeiture rate and the expected term of the underlying instruments. Any changes in the estimates or inputs utilized to determine fair value could have a significant impact on the Company's future operating results or on other components of shareholders' equity.
- **Inventories** - Inventories are valued at the lower of cost and net realizable value. Cost of inventory includes cost of purchase (purchase price, import duties, transport, handling, and other costs directly attributable to the acquisition of inventories), cost of conversion, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value for inventories is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Provisions are made in profit or loss of the current period on any difference between book value and net realizable value.

NeutriSci International Inc.

Notes to the Condensed Consolidated Interim Financial Statements
(Unaudited – Prepared by Management)
(Expressed in US dollars)
As at and for the nine months ended September 30, 2015

4. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (continued)

(a) Critical accounting estimates (continued)

- Estimated product returns - Revenue from product sales is recognized net of estimated sales discounts, credits, returns, rebates and allowances. The return allowance is determined based on an analysis of the historical rate of returns, industry return data, and current market conditions, which is applied directly against sales.
- Impairment of non-financial assets - The Company assesses impairment at each reporting date by evaluating conditions specific to the Company that may lead to asset impairment. The recoverable amount of an asset or a cash-generating unit ("CGU") is determined using the greater of fair value less costs to sell and value in use which requires the use of various judgments, estimates, and assumptions. The Company identifies CGUs as identifiable groups of assets that are largely independent of the cash inflows from other assets or groups of assets. Value in use calculations require estimations of discount rates and future cash flows derived from revenue growth, gross margin and operating costs. Fair value less costs to sell calculations require the Company to estimate fair value of an asset or a CGU using market values of similar assets as well as estimations of the related costs to sell.

(b) Critical accounting judgements

Information about critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the condensed consolidated interim financial statements are, but are not limited to, the following:

- Deferred income taxes – judgments are made by management to determine the likelihood of whether deferred income tax assets at the end of the reporting period will be realized from future taxable earnings. To the extent that assumptions regarding future profitability change, there can be an increase or decrease in the amounts recognized in respect of deferred tax assets as well as the amounts recognized in profit or loss in the period in which the change occurs.
- Functional currency - The functional currency for the Company and each of the Company's subsidiaries is the currency of the primary economic environment in which the respective entity operates; the Company has determined the functional currency of each entity to be the US dollar. Such determination involves certain judgments to identify the primary economic environment. The Company reconsiders the functional currency of its subsidiaries if there is a change in events and/or conditions which determine the primary economic environment.
- Going concern – As disclosed in Note 1 to these condensed consolidated interim financial statements.

5. INVENTORY

	Packaging Materials	Finished Goods	Total
Balance, December 31, 2014	\$ -	\$ 1,167,369	\$ 1,167,369
Additions	49,665	10,925	60,590
Cost of sales	(4,124)	(6,055)	(10,179)
Balance, September 30, 2015	\$ 45,541	\$ 1,172,239	\$ 1,217,780

NeutriSci International Inc.

Notes to the Condensed Consolidated Interim Financial Statements
(Unaudited – Prepared by Management)
(Expressed in US dollars)
As at and for the nine months ended September 30, 2015

6. EQUIPMENT

	Furniture and Equipment	Computer Equipment	Total
Costs:			
Balance, December 31, 2014	\$ 75,498	\$ 6,692	\$ 82,190
Balance, September 30, 2015	\$ 75,498	\$ 6,692	\$ 82,190
Accumulated Amortization:			
Balance, December 31, 2014	\$ 51,482	\$ 5,247	\$ 56,729
Amortization	5,208	788	5,996
Balance, September 30, 2015	\$ 56,690	\$ 6,035	\$ 62,725
Net Book Value:			
December 31, 2014	\$ 24,016	\$ 1,445	\$ 25,461
Balance, September 30, 2015	\$ 18,808	\$ 657	\$ 19,465

7. NOTES PAYABLE

	Promissory Note	Other Note Payable	Loan Payable	Total
Balance, December 31, 2014	\$ 550,000	\$ 500,000	\$ 44,730	\$ 1,094,730
Repayments	(550,000)	-	(350,644)	(900,644)
Interest expense	-	-	10,753	10,753
Proceeds	-	-	369,820	369,820
Balance, September 30, 2015	\$ -	\$ 500,000	\$ 74,660	\$ 574,659

(a) Promissory Note Payable

On November 5, 2014, NeutriSci entered into a debt settlement agreement to settle the outstanding balance of the promissory note payable and related interest. In accordance with the amended agreement, and in full settlement of the promissory note, NeutriSci paid \$1,250,000 on November 26, 2014, and was required to make an additional five monthly payments of \$110,000 commencing on March 26, 2015. At the option of the holder of the promissory note, the balance of payments was convertible into common shares of NeutriSci, as constituted on November 26, 2014, at a price of Cdn\$0.75 per share. This promissory note payable has been repaid in full.

(b) Other Note Payable

The Other Note payable is unsecured, non-interest bearing, and is to be repaid in equal monthly installments with the final payment due September 18, 2015. As at September 30, 2015 no payments have been made towards this obligation.

(c) Loan Payable

As at September 30, 2015, the Company had a loan payable of Cdn\$100,000. This loan was provided by an unrelated third party, is unsecured, non-interest bearing and is due on June 10, 2016. The loan payable at December 31, 2014 was unsecured, and pertains to a Cdn\$50,000 loan that was repayable in the amount of Cdn\$55,000. The loan was repaid in full in the amount of Cdn\$55,000 during the nine months ended September 30, 2015. During the period, the Company entered into two additional unsecured promissory notes with unrelated third parties. The first note was for Cdn\$171,310, bearing interest at 12% per annum, the second was for Cdn\$73,850 and was non-interest bearing. These two notes were repaid on August 20, 2015, for Cdn\$177,063, including interest, and Cdn\$73,850, respectively.

NeutriSci International Inc.

Notes to the Condensed Consolidated Interim Financial Statements
(Unaudited – Prepared by Management)
(Expressed in US dollars)
As at and for the nine months ended September 30, 2015

8. RELATED PARTY TRANSACTIONS

The Company had transactions with the following related parties:

Related party	Relationship
VMC Holdings Inc.	Former CEO, President, director
Omni Investments Investment Strategies	Former Vice President Business Development, director
Tingle Merrett LLP	Former director of the Company is a partner at the law firm
Cassels Brock & Blackwell LLP	Director of the Company is a partner at the law firm
Emprise Capital Corp.	Directors and officers in common with the Company

The Company incurred the following expenses with companies controlled by officers and directors of the Company.

Name of the related party	Nature of the Services	For the nine months ended September 30, 2015	For the twelve months ended September 30, 2014
VMC Holdings Inc.	Consulting	\$ -	\$ 47,382
Omni Investments Investment Strategies	Consulting	-	51,030
Tingle Merrett LLP	Legal	-	44,729
Cassels Brock & Blackwell LLP	Legal	5,702	-
Emprise Capital Corp.	Management	107,150	-
		\$ 112,852	\$ 143,141

The following table comprises amounts due to related parties included with accounts payable and accrued liabilities.

	September 30, 2015	December 31, 2014
Officers of the Company	\$ 12,827	\$ 4,202
Omni Investments Investment Strategies	-	9,051
Emprise Capital Corp.	-	388
Total	\$ 12,827	\$ 13,641

The following table compares amounts due from related parties as at:

	September 30, 2015	December 31, 2014
Due from a Officer/Director	\$ 30,922	\$ 14,311
Former CEO/Director	17,215	4,425
	\$ 48,137	\$ 18,736

Key management personnel compensation:

Key management includes the Company's directors, officers and senior management.

	For the nine months ended September 30, 2015	For the twelve months ended September 30, 2014
Salaries and related benefits	\$ 167,020	\$ 82,849
Consulting fees	-	148,647
Share-based compensation	114,077	-
Management fees	107,150	-
	\$ 388,247	\$ 231,496

NeutriSci International Inc.

Notes to the Condensed Consolidated Interim Financial Statements
(Unaudited – Prepared by Management)
(Expressed in US dollars)
As at and for the nine months ended September 30, 2015

9. SHARE CAPITAL

(a) Authorized

Unlimited number of common shares without par value
Unlimited number of preferred shares without par value

(b) Series A, B and C Preferred Shares

These preferred shares automatically converted into common shares of the Company on the following specified release dates.

	Series A	Series B	Series C	Total
Balance, December 31, 2014	6,758,938	8,110,723	8,110,719	22,980,380
Converted into common shares	(6,758,938)	(8,110,723)	(8,110,719)	(22,980,380)
Balance, September 30, 2015	-	-	-	-

The series A, B and C preferred shares automatically converted into common shares of the Company on February 26, 2015, May 25, 2015 and August 26, 2015, respectively.

(c) Common share issuances

During the period, 6,758,938 common shares were issued on the conversion of the Company's series A preferred shares, 8,110,723 common shares were issued on the conversion of the Company's series B preferred shares, and 8,110,719 common shares were issued on the conversion of the Company's series C preferred shares.

On February 25, 2015, the Company issued 200,000 common shares pursuant to a marketing and branding partnership with Brand Fever Inc. The fair value of these shares, being \$120,000, was determined using the most recently completed common share financing at Cdn\$0.75 per common share. The value of these shares has been recognized in the Company's share capital amount, with the corresponding entry recognized as a marketing expense.

On July 17, 2015, the Company completed a non-brokered private placement of 2,222,223 common shares, at Cdn\$0.18 per share, for gross proceeds of Cdn\$400,000. In connection with this closing, the Company paid a cash finders' fee of Cdn\$15,754, which has been recorded as share issuance costs.

On August 20, 2015, the Company completed a non-brokered private placement of 1,200,000 common shares, at Cdn\$0.18 per share, for gross proceeds of Cdn\$216,000. In connection with this closing, the Company paid a cash finders' fee of Cdn\$7,129, which has been recorded as share issuance costs.

On September 30, 2015, the Company completed a non-brokered private placement of 1,722,333 units, at Cdn\$0.18 per unit, for gross proceeds of Cdn\$310,020. Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share at a price of Cdn\$0.25 per share until September 30, 2017. In connection with this closing, the Company paid a cash finders' fee of Cdn\$4,200, which has been recorded as share issuance costs.

See also Subsequent Events note 11.

NeutriSci International Inc.

Notes to the Condensed Consolidated Interim Financial Statements
(Unaudited – Prepared by Management)
(Expressed in US dollars)
As at and for the nine months ended September 30, 2015

9. SHARE CAPITAL (continued)

(d) Stock options

There were no stock options granted, or exercised during the nine months ended September 30, 2015.

A summary of the Company's stock option activity is as follows:

	Number of Options	Weighted Average Exercise Price (\$Cdn)
Balance, December 31, 2014	1,400,000	\$ 0.67
Cancelled	(33,334)	0.30
Balance, September 30, 2015	1,366,666	\$ 0.68

A summary of the Company's stock options outstanding at September 30, 2015 are as follows:

Grant Date	Number of Options outstanding	Number of Options exercisable	Weighted Average Exercise Price (\$Cdn)	Expiry date	Weighted Average Remaining contractual life (years)
July 15, 2013	216,666	216,666	\$ 0.30	July 15, 2018	2.79
November 26, 2014	800,000	400,000	\$ 0.75	November 26, 2019	4.16
December 3, 2014	350,000	350,000	\$ 0.75	December 3, 2019	4.19
Total	1,366,666	966,666	\$ 0.68		3.95

The Company recognized \$276,335 in share-based compensation relating to stock options that vested during the nine months ended September 30, 2015.

(d) Warrants

The following summarizes the warrant activity:

	Number of Warrants	Weighted average exercise price (\$Cdn)
Total warrants outstanding, December 31, 2014	3,633,631	\$ 0.91
Warrants expired/unexercised	(425,000)	\$ 0.59
Warrants issued as part of private placement	1,722,333	\$ 0.25
Total warrants outstanding, September 30, 2015	4,930,964	\$ 0.71

A summary of warrants outstanding at September 30, 2015 are as follows:

Number of Warrants outstanding	Weighted Average Exercise Prices (\$Cdn)	Expiry date	Weighted Average Remaining contractual life (years)
340,000	\$0.59	March 25, 2016	0.48
2,868,631	\$1.00	May 26, 2016	0.65
1,722,333	\$0.25	September 30, 2017	2.00
4,930,964	\$0.71		1.11

See also Subsequent Events note 11.

NeutriSci International Inc.

Notes to the Condensed Consolidated Interim Financial Statements
(Unaudited – Prepared by Management)
(Expressed in US dollars)
As at and for the nine months ended September 30, 2015

9. SHARE CAPITAL (continued)

(e) Broker Warrants

No broker warrants were issued, cancelled, expired or exercised during the nine months ended September 30, 2015.

A summary of broker warrants outstanding at September 30, 2015 are as follows:

	Number of Warrants outstanding	Weighted Average Exercise Prices	Expiry date	Weighted Average Remaining contractual life (years)
November 26, 2014	221,669	Cdn\$1.00	May 26, 2016	0.65

See also Subsequent Events note 11.

10. EXPENSES BY NATURE

	For the three months ended September 30,		For the nine months ended September 30,	For the twelve months ended September 30,
	2015	2014	2015	2014
Operating Expenses:				
Advertising and promotions	\$ 41,288	\$ 4,499	\$ 254,650	\$ 93,901
Amortization	-	2,997	5,996	10,082
Consulting fees	43,408	86,570	134,387	378,612
Insurance	-	-	10,513	-
Miscellaneous	653	-	4,248	-
Product development	-	-	3,000	-
Property taxes	-	-	5,000	1,138
Rent	4,595	7,056	23,873	31,456
Salaries and benefits	58,453	29,068	177,700	155,747
Share-based compensation (Note 9)	103,204	-	276,335	41,073
Storage and handling costs	14,147	10,578	44,044	54,883
Telephone and utilities	3,019	5,629	13,184	18,168
Travel and automobile expenses	12,579	(1,906)	26,529	52,295
	\$ 281,346	\$ 144,491	\$ 979,459	\$ 837,355
General and Administrative Expenses:				
Management fees	\$ 34,250	\$ -	\$ 107,150	\$ -
Meals and entertainment	925	5,803	11,708	30,585
Office and Misc	5,017	5,870	27,643	53,236
Professional fees	6,075	24,279	92,802	126,372
Transfer Agent and Filing Fees	6,524	-	31,645	-
	\$ 52,791	\$ 35,952	\$ 270,948	\$ 210,193

NeutriSci International Inc.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited – Prepared by Management)

(Expressed in US dollars)

As at and for the nine months ended September 30, 2015

10. EXPENSES BY NATURE (continued)

Finance Fees:

Accretion on note payable	\$ -	\$ -	\$ -	\$ 281,546
Interest expense	3,676	130,515	9,429	313,602
Finances fees	7,902	-	7,902	215,976
	\$ 11,578	\$ 130,515	\$ 17,331	\$ 811,124

11. SUBSEQUENT EVENTS

On November 25, 2015, the Company completed a non-brokered private placement of 13,013,000 units (the "Units"), at Cdn\$0.18 per unit, for gross proceeds of Cdn\$2,342,340. Each Unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share at a price of Cdn\$0.25 per share for a period of two years from closing. In connection with the private placement, the Company paid a cash commission of Cdn\$127,411, and issued broker warrants to purchase 707,840 Units. Each broker's warrant entitles the holder to acquire a Unit, at a price of Cdn\$0.18 per Unit. All securities issued in connection with the private placement are subject to a hold period expiring March 26, 2016.